Prospective Grant of Exclusive License: Immunoconjugates Having High Binding Affinity, 76353 [E6-21667]

Download as PDF Federal Register / Vol. 71, No. 244 / Wednesday, December 20, 2006 / Notices National Institutes of Health Prospective Grant of Exclusive License: Immunoconjugates Having High Binding Affinity National Institutes of Health, Public Health Service, HHS. ACTION: Notice. sroberts on PROD1PC70 with NOTICES AGENCY: SUMMARY: This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR 404.7(a)(1)(i), that the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an exclusive patent license to practice the inventions embodied in U.S. Patent No. 7,081,518, issued July 25, 2006, entitled ‘‘AntiMesothelin Antibodies Having HighAffinity Binding’’ [E–139–1999/0–US– 07]; European Patent Application No. 00937925.6, filed May 26, 2000, entitled ‘‘Immunoconjugates Having High Binding Affinity’’ [E–139–1999/0–EP– 04]; Japanese Patent Application No. 2001–500670, filed May 26, 2000, entitled ‘‘Immunoconjugates Having High Binding Affinity’’ [E–139–1999/0– JP–05]; Mexican Patent Application No. PA/a/2001/01195, filed May 26, 2000, entitled ‘‘Immunoconjugates Having High Binding Affinity’’ [E–139–1999/0– MX–06]; and Canadian Patent Application No. 2374398, filed May 26, 2000, entitled ‘‘Immunoconjugates Having High Binding Affinity’’ [E–139– 1999/0–CA–03] to Cambridge Antibody Technology, Ltd., which has offices in Cambridge, United Kingdom. The patent rights in these inventions have been assigned to the United States of America. The prospective exclusive license territory may be worldwide, and the field of use may be limited to the use of the SSIP immunoconjugate and variants thereof for the treatment of mesothelin expressing cancers. DATES: Only written comments and/or applications for a license which are received by the NIH Office of Technology Transfer on or before February 20, 2007 will be considered. ADDRESSES: Requests for copies of the patent application, inquiries, comments, and other materials relating to the contemplated exclusive license should be directed to: Jesse S. Kindra, J.D., M.S., Technology Licensing Specialist, Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, MD 20852–3804; Telephone: (301) 435– 5559; Facsimile: (301) 402–0220; E-mail: kindraj@mail.nih.gov. VerDate Aug<31>2005 20:03 Dec 19, 2006 Jkt 211001 This technology relates to an improved antimesothelin antibody (SS1) based on affinity maturation, which involves somatic hypermutation of the variable region. The technology also includes additional antibody variants other than SS1. The prospective exclusive license will be royalty bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. The prospective exclusive license may be granted unless within sixty (60) days from the date of this published notice, the NIH receives written evidence and argument that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7. Applications for a license in the field of use filed in response to this notice will be treated as objections to the grant of the contemplated exclusive license. Comments and objections submitted to this notice will not be made available for public inspection and, to the extent permitted by law, will not be released under the Freedom of Information Act, 5 U.S.C. 552. SUPPLEMENTARY INFORMATION: DEPARTMENT OF HEALTH AND HUMAN SERVICES Dated: December 12, 2006. Steven M. Ferguson, Director, Division of Technology Development and Transfer, Office of Technology Transfer, National Institutes of Health. [FR Doc. E6–21667 Filed 12–19–06; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HOMELAND SECURITY [OMB Control Number: 1651–0101] Submission for Review; Reinstatement Previously Discontinued Information Collection Request for the Fiscal Year 2003 State Domestic Preparedness Program Preparedness Directorate, National Preparedness Task Force, DHS. ACTION: Notice; 30-day notice of information collections under review: Reinstatement Previously Discontinued Information Collection Request for the Fiscal Year 2003 State Domestic Preparedness Program. AGENCY: SUMMARY: The Department of Homeland Security (DHS) has submitted the following information collection request (ICRs) to the Office of Management and Budget (OMB) for review and clearance in accordance with the Paperwork Reduction Action of 1995: 1600–0002, 1600–0003, 1600–0004, 1600–0005. The information collections were previously published in Federal Register on PO 00000 Frm 00083 Fmt 4703 Sfmt 4703 76353 October 12, 2006 allowing for OMB review and a 60-day public comment period. No Comments were received by DHS. The purpose of this notice is to allow an additional 30 days for public comments. Comments are encouraged and will be accepted until January 19, 2007 (Automatically tabulated by FR). This process is conducted in accordance with 5 CFR 1320.10. Comments: Interested persons are invited to submit written comments on the proposed information collection to the Office of Information and Regulatory Affairs, Office of Management and Budget. Comments should be addressed to Nathan Lesser, Desk Officer, Department of Homeland Security/ Preparedness, and sent via electronic mail to oira_submission@omb.eop.gov or faxed to (202) 395–6974. The Office of Management and Budget is particularly interested in comments which: (1) Evaluate whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information will have practical utility; (2) Evaluate the accuracy of the agency’s estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used; (3) Enhance the quality, utility, and clarity of the information to be collected; and (4) Minimize the burden of the collection of information on those who are to respond, including through the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology, e.g., permitting electronic submissions of responses. FOR FURTHER INFORMATION CONTACT: A copy of this ICR, with applicable supporting documentation, may be obtained by calling Nathan Lesser, Desk Officer, Department of Homeland Security Washington, DC 20528; and sent via electronic mail to oira_submission@omb.eop.gov of faxed to (202) 395–6974 (this is not a toll free number.) SUPPLEMENTARY INFORMATION: DATES: Analysis Agency: Department of Homeland Security, Preparedness Directorate, National Preparedness Task Force. Title: Fiscal Year 2003 State Domestic Preparedness Program. OMB No.: 1651–0101. E:\FR\FM\20DEN1.SGM 20DEN1

Agencies

[Federal Register Volume 71, Number 244 (Wednesday, December 20, 2006)]
[Notices]
[Page 76353]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E6-21667]



[[Page 76353]]

-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Prospective Grant of Exclusive License: Immunoconjugates Having 
High Binding Affinity

AGENCY: National Institutes of Health, Public Health Service, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 
CFR 404.7(a)(1)(i), that the National Institutes of Health, Department 
of Health and Human Services, is contemplating the grant of an 
exclusive patent license to practice the inventions embodied in U.S. 
Patent No. 7,081,518, issued July 25, 2006, entitled ``Anti-Mesothelin 
Antibodies Having High-Affinity Binding'' [E-139-1999/0-US-07]; 
European Patent Application No. 00937925.6, filed May 26, 2000, 
entitled ``Immunoconjugates Having High Binding Affinity'' [E-139-1999/
0-EP-04]; Japanese Patent Application No. 2001-500670, filed May 26, 
2000, entitled ``Immunoconjugates Having High Binding Affinity'' [E-
139-1999/0-JP-05]; Mexican Patent Application No. PA/a/2001/01195, 
filed May 26, 2000, entitled ``Immunoconjugates Having High Binding 
Affinity'' [E-139-1999/0-MX-06]; and Canadian Patent Application No. 
2374398, filed May 26, 2000, entitled ``Immunoconjugates Having High 
Binding Affinity'' [E-139-1999/0-CA-03] to Cambridge Antibody 
Technology, Ltd., which has offices in Cambridge, United Kingdom. The 
patent rights in these inventions have been assigned to the United 
States of America.
    The prospective exclusive license territory may be worldwide, and 
the field of use may be limited to the use of the SSIP immunoconjugate 
and variants thereof for the treatment of mesothelin expressing 
cancers.

DATES: Only written comments and/or applications for a license which 
are received by the NIH Office of Technology Transfer on or before 
February 20, 2007 will be considered.

ADDRESSES: Requests for copies of the patent application, inquiries, 
comments, and other materials relating to the contemplated exclusive 
license should be directed to: Jesse S. Kindra, J.D., M.S., Technology 
Licensing Specialist, Office of Technology Transfer, National 
Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, 
MD 20852-3804; Telephone: (301) 435-5559; Facsimile: (301) 402-0220; E-
mail: kindraj@mail.nih.gov.

SUPPLEMENTARY INFORMATION: This technology relates to an improved anti-
mesothelin antibody (SS1) based on affinity maturation, which involves 
somatic hypermutation of the variable region. The technology also 
includes additional antibody variants other than SS1.
    The prospective exclusive license will be royalty bearing and will 
comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. 
The prospective exclusive license may be granted unless within sixty 
(60) days from the date of this published notice, the NIH receives 
written evidence and argument that establishes that the grant of the 
license would not be consistent with the requirements of 35 U.S.C. 209 
and 37 CFR 404.7.
    Applications for a license in the field of use filed in response to 
this notice will be treated as objections to the grant of the 
contemplated exclusive license. Comments and objections submitted to 
this notice will not be made available for public inspection and, to 
the extent permitted by law, will not be released under the Freedom of 
Information Act, 5 U.S.C. 552.

    Dated: December 12, 2006.
Steven M. Ferguson,
Director, Division of Technology Development and Transfer, Office of 
Technology Transfer, National Institutes of Health.
 [FR Doc. E6-21667 Filed 12-19-06; 8:45 am]
BILLING CODE 4140-01-P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.